Amgen profit beats Street view, will not raise prices again in 2018
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Amgen (AMGN) PT Raised to $179 at Baird
July 27, 2018 8:48 AM EDTBaird raised its price target on Amgen (NASDAQ: AMGN) to $179.00 (from $165.00) while maintaining a Neutral rating.
... MoreAmgen (AMGN) PT Raised to $205 at Cowen Following 'Beat and Raise'
July 27, 2018 8:24 AM EDTCowen raised its price target on Amgen (NASDAQ: AMGN) to $205.00 (from $204.00) while maintaining a Outperform rating.
Analyst Phil Nadeau commented, "Amgen reported Q2 revenue of $6.06B (+4% Y/Y, vs. consensus of $5.73BE) and non-GAAP EPS of $3.83 (+17% Y/Y, vs. consensus of $3.54E). Amgen both... More
Bristol-Myers Squibb Co. (BMY) PT Raised to $57 at BMO Capital
July 27, 2018 8:21 AM EDTBMO Capital raised its price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $57.00 (from $51.00) while maintaining a Market Perform rating.
Analyst Alex Arfaei commented, "Bristol had a good 2Q but expectations had risen, which, coupled with untimely (CHMP RCC) news, pressured BMY. The... More
Amgen (AMGN) PT Raised to $195 at Barclays
July 27, 2018 6:56 AM EDTBarclays raised its price target on Amgen (NASDAQ: AMGN) to $195.00 (from $180.00) while maintaining a Equalweight rating following the company's 2Q earnings report.
Amgens portfolio looks poised to deliver flat growth in 2018e, which, in Barclays view, will likely keep... More
Amgen (AMGN) PT Raised to $210 at Piper Jaffray Following 2Q
July 27, 2018 6:45 AM EDTPiper Jaffray raised its price target on Amgen (NASDAQ: AMGN) to $210.00 (from $190.00) while maintaining a Overweight rating following the company's 2Q earnings report. AMGN posted Q218 non-GAAP EPS of $3.83, well ahead of consensus $3.55. Upside was operationally driven as revenue beat handily (total revenue was... More
